11 powodów, dla których warto stosować spironolakton – przegląd doniesień naukowych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2015
Słowa kluczowe:
spironolakton, aldosteron, antagoniści receptora mineralokortykoidowego, nadciśnienie tętnicze, niewydolność serca, choroby układu krążenia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Spironolakton jest najdłużej dostępnym na rynku i najlepiej zbadanym przedstawicielem grupy antagonistów receptora mineralokortykoidowego – leków, które są coraz częściej stosowane w leczeniu pacjentów z chorobami układu sercowo-naczyniowego, zwłaszcza z nadciśnieniem tętniczym, pierwotnym hiperaldosteronizmem i niewydolnością serca. Spironolakton jest postrzegany jako lek przydatny głównie u pacjentów z hiperaldosteronizmem, skurczową niewydolnością serca oraz nadciśnieniem opornym, ale ma on również inne zalety, które wpływają na jego wartość w wielu innych sytuacjach klinicznych. W artykule dokonano przeglądu najważniejszych dowodów z badań naukowych dotyczących stosowania spironolaktonu w różnych grupach pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Jędrusik , P. (2015). 11 powodów, dla których warto stosować spironolakton – przegląd doniesień naukowych . Medycyna Faktów , 8(2(27), 30-38. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2308
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
2. Vizzardi E., Nodari S., Caretta G. et al.: Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am. J. Med. Sci. 2014; 347: 271-276.
3. Chapman N., Dobson J., Wilson S. et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 1-7.
4. Vaclavik J., Sedlak R., Plachy M. et al.: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
5. Rodilla E., Costa J.A., Perez-Lahiguera F. et al.: Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev. Esp. Cardiol. 2009; 62: 158-166.
6. Viera A.J.: Resistant hypertension. J. Am. Board. Fam. Med. 2012; 25: 487-495.
7. Batterink J., Stabler S.N., Tejani A.M. et al.: Spironolactone for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008169. [DOI: 10.1002/14651858.CD008169.pub2].
8. Adlin E.V., Marks A.D., Channick B.J.: Spironolactone and hydrochlorothiazide in essential hypertension. Arch. Intern. Med. 1972; 130: 855-858.
9. Kreeft J.H., Larochelle P., Ogilive R.I.: Comparison of chlorthalidone and spironolactone in low-renin essential hypertension. Can. Med. Assoc. J. 1983; 128: 31-34.
10. Karlberg B.E., Kagedal B., Tegler L. et al.: Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity. Am. J. Cardiol. 1976; 37: 642-649.
11. Henry M., Wehrlen M., Pelletier B. et al.: Spironolactone versus nifedipine in essential hypertension. Am. J. Cardiol. 1990; 65: 36K-38K.
12. Plouin P.F., Battaglia C., Alhenc-Gélas F. et al.: Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty? Am. J. Hypertens. 1991; 4: 356-362.
13. Catena C., Colussi G.L., Lapenna R. et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
14. Gaddam K., Corros C., Pimenta E. et al.: Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 1137-1142.
15. Williams R.S., deLemos J.A., Dimas V. et al.: Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin. Cardiol. 2011; 34: 415-419.
16. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
17. Bianchi S., Bigazzi R., Campese V.M.: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
18. Navaneethan S.D., Nigwekar S.U., Sehgal A.R. et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 542-551.
19. Schjoedt K.J., Rossing K., Juhl T.R. et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-542.
20. Oxlund C., Henriksen J., Tarnow L. et al.: Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomised clinical trial. J. Hypertens. 2013; 31: 2094-2102.
21. Bomback A.S., Muskala P., Bald E. et al.: Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009; 72: 449-456.
22. Roongsritong C., Sutthiwan P., Bradley J. et al.: Spironolactone improves diastolic function in the elderly. Clin. Cardiol. 2005; 28: 484-487.
23. Sato A., Hayashi M., Saruta T.: Relative long-term effects of spironolactone in conjunction with angiotensin-converting enzyme inhibitors on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens. Res. 2002; 25: 837-842.
24. Gupta A., Schiros C.G., Gaddam K.K. et al.: Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J. Hum. Hypertens. 2015; 29: 241-246.
25. Edelmann F., Wachter R., Schmidt A.G. et al.: Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
26. Pitt B., Pfeffer M.A., Assmann S.F. et al.: Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014; 370: 1383-1392.
27. Pfeffer M.A., Claggett B., Assmann S.F. et al.: Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
28. Zile M.R., Gaasch W.H.: UpToDate: Treatment and prognosis of diastolic heart failure, 2014 [online: www.uptodate.com/contents/treatment-and- prognosis-of-diastolic-heart-failure].
29. Yemisci A., Gorgulu A., Piskin S.: Effects and side-effects of spironolactone therapy in women with acne. J. Eur. Acad. Dermatol. Venereol. 2005; 19: 163-166.
30. Shaw J.C.: Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J. Am. Acad. Dermatol. 2000; 43: 498-502.
31. Sinclair R., Wewerinke M., Jolley D.: Treatment of female pattern hair loss with oral antiandrogens. Br. J. Dermatol. 2005; 152: 466-473.
32. Radosh L.: Drug treatments for polycystic ovary syndrome. Am. Fam. Physician 2009; 79: 671-676.
33. Zulian E., Sartorato P., Benedini S.: Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J. Endocrinol. Invest. 2005; 28: 49-53.
34. Maron B., Leopold J.: Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010; 121: 934-939.
35. Khosla N., Kalaitzidis R., Bakris G.L.: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 2009; 30: 418-424.
36. Engbaek M., Hjerrild M., Hallas J. et al.: The effect of low-dose spironolactone on resistant hypertension. J. Am. Soc. Hypertens. 2010; 4: 290-294.
37. Heshka J., Ruzicka M., Hiremath S. et al.: Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J. Am. Soc. Hypertens. 2010: 4: 295-301.
38. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004; 351: 543-551.
39. Wei L., Struthers A.D., Fahey T. et al.: Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340: c1768.
40. Edwards N.C., Steeds R.P., Chue C.D. et al.: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br. J. Clin. Pharmacol. 2012; 73: 447-454.
41. Ruilope L.M.: Safety aspects of aldosterone-blocking drugs. Eur. Heart J. Suppl. 2011; 13(suppl. B): B40-B42.
42. Mackenzie I.S., MacDonald T.M., Thompson A. et al.: Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 2012; 345: e4447.
2. Vizzardi E., Nodari S., Caretta G. et al.: Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am. J. Med. Sci. 2014; 347: 271-276.
3. Chapman N., Dobson J., Wilson S. et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 1-7.
4. Vaclavik J., Sedlak R., Plachy M. et al.: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075.
5. Rodilla E., Costa J.A., Perez-Lahiguera F. et al.: Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev. Esp. Cardiol. 2009; 62: 158-166.
6. Viera A.J.: Resistant hypertension. J. Am. Board. Fam. Med. 2012; 25: 487-495.
7. Batterink J., Stabler S.N., Tejani A.M. et al.: Spironolactone for hypertension. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD008169. [DOI: 10.1002/14651858.CD008169.pub2].
8. Adlin E.V., Marks A.D., Channick B.J.: Spironolactone and hydrochlorothiazide in essential hypertension. Arch. Intern. Med. 1972; 130: 855-858.
9. Kreeft J.H., Larochelle P., Ogilive R.I.: Comparison of chlorthalidone and spironolactone in low-renin essential hypertension. Can. Med. Assoc. J. 1983; 128: 31-34.
10. Karlberg B.E., Kagedal B., Tegler L. et al.: Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity. Am. J. Cardiol. 1976; 37: 642-649.
11. Henry M., Wehrlen M., Pelletier B. et al.: Spironolactone versus nifedipine in essential hypertension. Am. J. Cardiol. 1990; 65: 36K-38K.
12. Plouin P.F., Battaglia C., Alhenc-Gélas F. et al.: Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty? Am. J. Hypertens. 1991; 4: 356-362.
13. Catena C., Colussi G.L., Lapenna R. et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
14. Gaddam K., Corros C., Pimenta E. et al.: Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 1137-1142.
15. Williams R.S., deLemos J.A., Dimas V. et al.: Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin. Cardiol. 2011; 34: 415-419.
16. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
17. Bianchi S., Bigazzi R., Campese V.M.: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
18. Navaneethan S.D., Nigwekar S.U., Sehgal A.R. et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 542-551.
19. Schjoedt K.J., Rossing K., Juhl T.R. et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006; 70: 536-542.
20. Oxlund C., Henriksen J., Tarnow L. et al.: Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomised clinical trial. J. Hypertens. 2013; 31: 2094-2102.
21. Bomback A.S., Muskala P., Bald E. et al.: Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009; 72: 449-456.
22. Roongsritong C., Sutthiwan P., Bradley J. et al.: Spironolactone improves diastolic function in the elderly. Clin. Cardiol. 2005; 28: 484-487.
23. Sato A., Hayashi M., Saruta T.: Relative long-term effects of spironolactone in conjunction with angiotensin-converting enzyme inhibitors on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens. Res. 2002; 25: 837-842.
24. Gupta A., Schiros C.G., Gaddam K.K. et al.: Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J. Hum. Hypertens. 2015; 29: 241-246.
25. Edelmann F., Wachter R., Schmidt A.G. et al.: Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
26. Pitt B., Pfeffer M.A., Assmann S.F. et al.: Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014; 370: 1383-1392.
27. Pfeffer M.A., Claggett B., Assmann S.F. et al.: Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
28. Zile M.R., Gaasch W.H.: UpToDate: Treatment and prognosis of diastolic heart failure, 2014 [online: www.uptodate.com/contents/treatment-and- prognosis-of-diastolic-heart-failure].
29. Yemisci A., Gorgulu A., Piskin S.: Effects and side-effects of spironolactone therapy in women with acne. J. Eur. Acad. Dermatol. Venereol. 2005; 19: 163-166.
30. Shaw J.C.: Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J. Am. Acad. Dermatol. 2000; 43: 498-502.
31. Sinclair R., Wewerinke M., Jolley D.: Treatment of female pattern hair loss with oral antiandrogens. Br. J. Dermatol. 2005; 152: 466-473.
32. Radosh L.: Drug treatments for polycystic ovary syndrome. Am. Fam. Physician 2009; 79: 671-676.
33. Zulian E., Sartorato P., Benedini S.: Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J. Endocrinol. Invest. 2005; 28: 49-53.
34. Maron B., Leopold J.: Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010; 121: 934-939.
35. Khosla N., Kalaitzidis R., Bakris G.L.: Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 2009; 30: 418-424.
36. Engbaek M., Hjerrild M., Hallas J. et al.: The effect of low-dose spironolactone on resistant hypertension. J. Am. Soc. Hypertens. 2010; 4: 290-294.
37. Heshka J., Ruzicka M., Hiremath S. et al.: Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J. Am. Soc. Hypertens. 2010: 4: 295-301.
38. Juurlink D.N., Mamdani M.M., Lee D.S. et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 2004; 351: 543-551.
39. Wei L., Struthers A.D., Fahey T. et al.: Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340: c1768.
40. Edwards N.C., Steeds R.P., Chue C.D. et al.: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br. J. Clin. Pharmacol. 2012; 73: 447-454.
41. Ruilope L.M.: Safety aspects of aldosterone-blocking drugs. Eur. Heart J. Suppl. 2011; 13(suppl. B): B40-B42.
42. Mackenzie I.S., MacDonald T.M., Thompson A. et al.: Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 2012; 345: e4447.